Developing new drugs for the treatment of drug-resistant tuberculosis: a regulatory perspective (Q37257908)

19 August 2017

1 reference

title

Developing new drugs for the treatment of drug-resistant tuberculosis: a regulatory perspective (English)

1 reference

19 August 2017

0 references

Leonard V Sacks

1

1 reference

PubMed ID

18762157

19 August 2017

Rachel E Behrman

series ordinal

2

1 reference

19 August 2017

1 August 2008

1 reference

19 August 2017

1 reference

19 August 2017

88 Suppl 1

1 reference

19 August 2017

S93-100

1 reference

Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa

19 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970040-4

7 January 2021

Time trends in primary HIV-1 drug resistance among recently infected persons

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970040-4

7 January 2021

The changing epidemiology of Staphylococcus aureus?

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970040-4

7 January 2021

USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970040-4

7 January 2021

Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970040-4

7 January 2021

Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970040-4

7 January 2021

Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970040-4

7 January 2021

Treatment and Outcome Analysis of 205 Patients with Multidrug-resistant Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970040-4

7 January 2021

Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970040-4

7 January 2021

Multidrug-resistant tuberculosis management in resource-limited settings

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970040-4

7 January 2021

Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970040-4

7 January 2021

Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970040-4

7 January 2021

Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970040-4

7 January 2021

Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970040-4

7 January 2021

Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970040-4

7 January 2021

Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970040-4

7 January 2021

A comparison of outbreak- and nonoutbreak-related multidrug-resistant tuberculosis among human immunodeficiency virus-infected patients in a South African hospital

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970040-4

7 January 2021

Nosocomial spread of human immunodeficiency virus-related multidrug-resistant tuberculosis in Buenos Aires

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970040-4

7 January 2021

Spread of strain W, a highly drug-resistant strain of Mycobacterium tuberculosis, across the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970040-4

7 January 2021

Global incidence of multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970040-4

7 January 2021

Microscopic observation drug susceptibility assay, a rapid, reliable diagnostic test for multidrug-resistant tuberculosis suitable for use in resource-poor settings

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970040-4

7 January 2021

Evaluation of new anti-infective drugs for the treatment and prevention of tuberculosis. Infectious Diseases Society of America and the Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970040-4

7 January 2021

Sputum smear conversion during directly observed treatment for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970040-4

7 January 2021

10.1016/S1472-9792(08)70040-4

Identifiers

DOI

1 reference

19 August 2017

1 reference

PubMed ID

18762157